fig3

From: Overview of methodologies and statistical strategies in observational studies and meta-analyses on the risk of hepatocellular carcinoma in patients with chronic hepatitis B on entecavir or tenofovir therapy

Overview of methodologies and statistical strategies in observational studies and meta-analyses on the risk of hepatocellular carcinoma in patients with chronic hepatitis B on entecavir or tenofovir therapy

Figure 3. The effect of the presence of competing risk on the overestimation of cumulative incidence of hepatocellular carcinoma (HCC) by the Kaplan Meier method under (A) 20% of competing risk in all patients, (B) 40% competing risk in all patients, and (C) 20% and 40% of competing risk in 100 tenofovir disoproxil fumarate (TDF)- and 900 entecavir (ETV)-treated simulated patients respectively. Gray’s method that takes competing risk into account when estimating the cumulative incidence function is used as a reference.

fig3

Portico

Portico